Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | -$0.21 | N/A | -4.50% |
management commentary, guidance changes, and full analysis available with Pro.
| -4.50% |
Tone: Defensive
Overall, management expressed concerns about current market conditions. They are prioritizing cost management and operational improvements.
Management acknowledged the challenges faced during the quarter.
They emphasized a focus on improving operational efficiencies.
Veracyte's earnings report indicates that the company is still facing challenges, as evidenced by the EPS miss. The stock reacted negatively, dropping 1.2% after the announcement. Investors may be cautious due to the lack of guidance and management's defensive tone during the call.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AMEREN CORP
Nov 3, 2017